Neurocritical Care News

The FDA has approved Neuronetics’ NeuroStar Advanced Therapy for Mental Health, a transcranial magnetic stimulation system for treatment of anxiety symptoms in adults with major depressive disorder, the company announced in a press release.

The U.S. Supreme Court’s recent decision to overturn Roe v. Wade will compromise standard neurological care for approximately 40 million women in as many as 28 states, educators wrote in JAMA Neurology.

Adherence to a Mediterranean diet was associated with better cognitive performance and decreased learning and memory decline after 7 years among middle-aged and older Hispanic or Latino adults, per a study published in JAMA Network Open.

The FDA has granted approval to Azurity Pharmaceuticals Inc. for its oral adjunctive therapy to treat partial seizures in adolescents and adults aged 16 years and older with epilepsy.

Plasma p-tau217 proved an accurate blood-based biomarker of both tau and amyloid-beta pathological brain alterations for those with Down syndrome and may be used alone or with age as a covariate, per a study published in JAMA Neurology.

Patients with nonalcoholic fatty liver disease had an increased risk for dementia, with stronger risk existing for those with comorbid heart disease or stroke, according to a study published in Neurology.

Treatment with ketamine significantly improved seizure occurrence related to refractory status epilepticus in both neonates and children, according to results of a study published in Neurology.

Labcorp Diagnostics announced the launch of the first widely accessible blood test that provides direct evidence of neurodegeneration and neuronal injury.

For adults with migraine and repeated preventive treatment failures, eptinezumab produced significant reductive effects compared with placebo, along with acceptable safety and tolerability, per a study published in Lancet Neurology.

Patients with posttraumatic refractory intracranial hypertension treated with decompressive craniectomy showed reduced mortality and improved recovery at 24 months compared with standard care, per a study published in JAMA Neurology.